Ambalal Sarabhai Enterprises Ltd Stock Falls to 52-Week Low of Rs.25.8

Jan 20 2026 11:54 AM IST
share
Share Via
Ambalal Sarabhai Enterprises Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.25.8 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance concerns.
Ambalal Sarabhai Enterprises Ltd Stock Falls to 52-Week Low of Rs.25.8



Stock Price Movement and Market Context


The stock closed at Rs.25.8, down to its lowest level in the past year, despite outperforming its sector by 1.76% on the day. This decline contrasts with the broader market trend, where the Sensex opened flat but subsequently fell by 230.94 points, or 0.32%, closing at 82,976.44. The Sensex remains 3.84% below its 52-week high of 86,159.02 and has experienced a 3.25% loss over the past three weeks. Notably, the Sensex is trading below its 50-day moving average, although the 50-day average remains above the 200-day moving average, indicating mixed signals in market momentum.



Ambalal Sarabhai’s stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring the sustained downward pressure on the share price. The stock’s 52-week high was Rs.53.83, highlighting a near 52.1% decline over the last year.



Financial Performance and Fundamental Assessment


The company’s financial metrics reveal challenges that have contributed to the stock’s decline. Ambalal Sarabhai Enterprises Ltd has a Mojo Score of 23.0 and a Mojo Grade of Strong Sell, an upgrade from a previous Sell rating on 13 Jan 2025, reflecting deteriorated fundamentals. The Market Cap Grade stands at 4, indicating a relatively modest market capitalisation within its peer group.



Long-term financial indicators show a weak return on capital employed (ROCE) averaging 4.55%, with the most recent quarterly ROCE at 1.5. Net sales have grown at a subdued annual rate of 7.00% over the past five years, signalling limited expansion in revenue generation. The company’s profitability has also been under pressure, with the latest quarterly profit before tax (PBT) at a loss of Rs.-1.66 crore, a decline of 548.6% compared to the previous four-quarter average. Similarly, the quarterly profit after tax (PAT) stood at Rs.-0.56 crore, down 111.3% from the prior four-quarter average.



Operating cash flow for the year is notably negative at Rs.-17.62 crore, the lowest recorded, indicating cash generation difficulties. These financial results have contributed to the stock’s underperformance relative to benchmarks. Over the last year, Ambalal Sarabhai’s stock has delivered a negative return of 46.99%, significantly lagging the Sensex’s positive 7.68% return. The stock has also underperformed the BSE500 index over the last three years, one year, and three months.




Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!



  • - Current monthly selection

  • - Single best opportunity

  • - Elite universe pick


Get the Full Details →




Valuation and Shareholding Structure


Despite the weak financial performance, Ambalal Sarabhai Enterprises Ltd exhibits an attractive valuation profile. The company’s enterprise value to capital employed ratio stands at 1.3, suggesting the stock is trading at a discount relative to its capital base. The PEG ratio is 0.5, reflecting a low price-to-earnings growth multiple, which may be indicative of market expectations for subdued growth.



Profitability has shown some improvement over the past year, with profits rising by 24.8%, a contrast to the stock’s negative price performance. This divergence points to complexities in market valuation and investor sentiment. The majority of the company’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics.



Sector and Industry Positioning


Operating within the Pharmaceuticals & Biotechnology sector, Ambalal Sarabhai Enterprises Ltd faces competitive pressures and sector-specific challenges. The sector itself has experienced mixed performance, with the company’s stock underperforming its peers and broader indices. The company’s Mojo Grade of Strong Sell reflects its relative standing within the Pharmaceuticals & Biotechnology industry, signalling caution based on fundamental and market data.




Ambalal Sarabhai Enterprises Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!



  • - SwitchER analysis complete

  • - Superior alternatives found

  • - Multi-parameter evaluation


See Smarter Alternatives →




Summary of Key Metrics


To summarise, Ambalal Sarabhai Enterprises Ltd’s stock has declined to Rs.25.8, its lowest level in 52 weeks, reflecting a 46.99% loss over the past year. The company’s financial performance shows subdued sales growth, negative profitability in recent quarters, and negative operating cash flow. The stock trades below all major moving averages and has a Mojo Grade of Strong Sell, indicating weak fundamental strength. Valuation metrics suggest the stock is trading at a discount relative to capital employed and peers, with a PEG ratio of 0.5. The majority shareholding by non-institutional investors adds another dimension to the stock’s market profile.



While the broader market has experienced some volatility, Ambalal Sarabhai’s share price movement is primarily influenced by its internal financial and operational factors, as reflected in the detailed metrics and ratings.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News